Submit a BLA for AMT-130 to the FDA
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 24 Sep 2025
- Due
- 31 Mar 2026
- Checked
- 1 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“uniQure plans to submit a BLA in the first quarter of 2026”
What we found
Evidence strength A What the grades mean
The company did not submit the BLA in the first quarter of 2026 as planned; subsequent filings indicate the submission was delayed to the third quarter of 2026.
-
A uniQure N.V. 8-K filed 2026-06-17
“Company intends to submit the BLA in third quarter of 2026” ✓ confirmed on the page
-
A uniQure N.V. 10-Q filed 2026-07-29
“we expect to submit a BLA in the third quarter of 2026.” ✓ confirmed on the page
Market reaction: the shares moved +65.0% against the S&P 500 over the three sessions around the disclosure (16 Jun 2026 to 22 Jun 2026). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 1 versions
-
Version 1 · original · stated 24 Sep 2025
Deadline 31 Mar 2026 (“in the first quarter of 2026”) · wording expected
-
Version 2 · stated 29 Jul 2026
Deadline 30 Sep 2026 (“third quarter of 2026”) · wording expected
“the Company expects to submit a BLA in the third quarter of 2026”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory submission
- Indicative materiality
- High rules
- Action
- Submit
- Deliverable
- BLA for AMT-130
- Where
- U.S.
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Conditional
- Yes: pending approval
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-QURE-001923 · Corrections policy